{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T18:53:10Z","timestamp":1773168790679,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T00:00:00Z","timestamp":1592006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T00:00:00Z","timestamp":1592006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00415-020-09988-w","type":"journal-article","created":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T15:02:31Z","timestamp":1592060551000},"page":"2462-2468","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Refractory anti-NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature review"],"prefix":"10.1007","volume":"267","author":[{"given":"Serena Marita","family":"Lazzarin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8283-7079","authenticated-orcid":false,"given":"Marco","family":"Vabanesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6544-410X","authenticated-orcid":false,"given":"Giordano","family":"Cecchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna Franca","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Antonietta","family":"Volont\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Genchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3685-8311","authenticated-orcid":false,"given":"Antonino","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5987-5739","authenticated-orcid":false,"given":"Vittorio","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Beccaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena","family":"Mucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Peccatori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-0479","authenticated-orcid":false,"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Minicucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,13]]},"reference":[{"issue":"1","key":"9988_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/ana.21050","volume":"61","author":"J Dalmau","year":"2007","unstructured":"Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A et al (2007) Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61(1):25\u201336","journal-title":"Ann Neurol"},{"issue":"7","key":"9988_CR2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/cid\/cir1038","volume":"54","author":"MS Gable","year":"2012","unstructured":"Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA (2012) The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 54(7):899\u2013904","journal-title":"Clin Infect Dis"},{"issue":"1","key":"9988_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","volume":"10","author":"J Dalmau","year":"2011","unstructured":"Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R (2011) Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 10(1):63\u201374","journal-title":"Lancet Neurol"},{"issue":"4","key":"9988_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/WCO.0000000000000214","volume":"28","author":"L Silveira-Moriyama","year":"2015","unstructured":"Silveira-Moriyama L, Lin JP (2015) A field guide to current advances in paediatric movement disorders. Curr Opin Neurol 28(4):437\u2013446","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"9988_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","volume":"12","author":"MJ Titulaer","year":"2013","unstructured":"Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T et al (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12(2):157\u2013165","journal-title":"Lancet Neurol"},{"issue":"4","key":"9988_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1212\/WNL.0000000000003536","volume":"88","author":"F Scheibe","year":"2017","unstructured":"Scheibe F, Pruss H, Mengel AM, Kohler S, Numann A, Kohnlein M et al (2017) Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology 88(4):366\u2013370","journal-title":"Neurology"},{"key":"9988_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.pediatrneurol.2019.09.004","volume":"103","author":"R Cordani","year":"2020","unstructured":"Cordani R, Micalizzi C, Giacomini T, Gastaldi M, Franciotta D, Fioredda F et al (2020) Bortezomib-Responsive Refractory Anti-N-Methyl-d-Aspartate Receptor Encephalitis. Pediatr Neurol 103:61\u201364","journal-title":"Pediatr Neurol"},{"issue":"10","key":"9988_CR8","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jamaneurol.2016.2588","volume":"73","author":"V Behrendt","year":"2016","unstructured":"Behrendt V, Krogias C, Reinacher-Schick A, Gold R, Kleiter I (2016) Bortezomib treatment for patients with Anti-N-Methyl-d-aspartate receptor encephalitis. JAMA Neurol 73(10):1251\u20131253","journal-title":"JAMA Neurol"},{"key":"9988_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.clineuro.2016.06.003","volume":"147","author":"A Seifi","year":"2016","unstructured":"Seifi A, Kitchen DL (2016) Management of dyskinesia in anti-NMDAR encephalitis with tramadol. Clin Neurol Neurosurg 147:105\u2013107","journal-title":"Clin Neurol Neurosurg"},{"issue":"6","key":"9988_CR10","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1177\/0310057X19889369","volume":"47","author":"KM Ho","year":"2019","unstructured":"Ho KM (2019) Use of tramadol to attenuate severe dyskinesia in anti-N-methyl-D-aspartate receptor encephalitis. Anaesth Intensive Care 47(6):561\u2013562","journal-title":"Anaesth Intensive Care"},{"issue":"2","key":"9988_CR11","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00415-019-09607-3","volume":"267","author":"A Giordano","year":"2020","unstructured":"Giordano A, Fazio R, Gelibter S, Minicucci F, Vabanesi M, Anzalone N et al (2020) Diagnosing autoimmune encephalitis in a real-world single-centre setting. J Neurol 267(2):449\u2013460","journal-title":"J Neurol"},{"issue":"6","key":"9988_CR12","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1136\/jnnp-2018-318584","volume":"90","author":"JA Varley","year":"2019","unstructured":"Varley JA, Webb AJS, Balint B, Fung VSC, Sethi KD, Tijssen MAJ et al (2019) The movement disorder associated with NMDAR antibody-encephalitis is complex and characteristic: an expert video-rating study. J Neurol Neurosurg Psychiatry 90(6):724\u2013726","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9988_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/mds.25354","volume":"28","author":"JF Baizabal-Carvallo","year":"2013","unstructured":"Baizabal-Carvallo JF, Stocco A, Muscal E, Jankovic J (2013) The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord 28:543\u2013547","journal-title":"Mov Disord"},{"key":"9988_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/mds.26093","volume":"30","author":"JF Baizabal Carvallo","year":"2015","unstructured":"Baizabal Carvallo JF, Cardoso F, Jankovic J (2015) Myorhythmia: phenomenology, etiology, and treatment. Mov Disord 30:171\u2013179","journal-title":"Mov Disord"},{"key":"9988_CR15","doi-asserted-by":"publisher","first-page":"383125","DOI":"10.1155\/2013\/383125","volume":"2013","author":"M MacMahon","year":"2013","unstructured":"MacMahon M, Naysmith MR, McCallion S, Rhodes J (2013) Ketamine infusion associated with improved neurology in a patient with NMDA receptor encephalitis. Case Rep Crit Care 2013:383125. https:\/\/doi.org\/10.1155\/2013\/383125","journal-title":"Case Rep Crit Care"},{"issue":"5","key":"9988_CR16","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1213\/01.ANE.0000150961.24747.98","volume":"100","author":"K Hara","year":"2005","unstructured":"Hara K, Minami K, Sata T (2005) The effects of tramadol and its metabolite on glycine, \u03b3-aminobutyric acid, and N-Methyl-d-aspartate receptors expressed in xenopus oocytes. Anesth Analg 100(5):1400\u20131405","journal-title":"Anesth Analg"},{"key":"9988_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.clineuro.2017.05.024","volume":"160","author":"BA Dengler","year":"2017","unstructured":"Dengler BA, Kitchen D, Seifi A (2017) Tramadol may increase the efficacy of therapeutic plasma exchange in anti-NMDAR encephalitis. Clin Neurol Neurosurg 160:38\u201339","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"9988_CR18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1152\/physrev.00010.2016","volume":"97","author":"J Dalmau","year":"2017","unstructured":"Dalmau J, Geis C, Graus F (2017) Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev 97(2):839\u2013887","journal-title":"Physiol Rev"},{"key":"9988_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/ana.24195","volume":"76","author":"EH Moscato","year":"2014","unstructured":"Moscato EH, Peng X, Jain A, Parsons TD, Dalmau J, Balice-Gordon RJ (2014) Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 76:108\u2013119","journal-title":"Ann Neurol"},{"key":"9988_CR20","doi-asserted-by":"publisher","first-page":"11082","DOI":"10.1523\/JNEUROSCI.0064-12.2012","volume":"32","author":"AJ Gleichman","year":"2012","unstructured":"Gleichman AJ, Spruce LA, Dalmau J, Seeholzer SH, Lynch DR (2012) Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain. J Neurosci 32:11082\u201311094","journal-title":"J Neurosci"},{"issue":"7","key":"9988_CR21","doi-asserted-by":"publisher","first-page":"e0201021","DOI":"10.1371\/journal.pone.0201021","volume":"13","author":"Y Xu","year":"2018","unstructured":"Xu Y, Zhang K, Miao J, Zhao P, Lv M, Li J et al (2018) The spinal NR2BR\/ERK2 pathway as a target for the central sensitization of collagen-induced arthritis pain. PLoS ONE 13(7):e0201021","journal-title":"PLoS ONE"},{"issue":"17","key":"9988_CR22","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1111\/bph.13222","volume":"172","author":"D Lodge","year":"2015","unstructured":"Lodge D, Mercier MS (2015) Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol 172(17):4254\u20134276","journal-title":"Br J Pharmacol"},{"issue":"7","key":"9988_CR23","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","volume":"74","author":"T Alexander","year":"2015","unstructured":"Alexander T, Sarfert R, Klotsche J, Kuhl AA, Rubbert-Roth A, Lorenz HM et al (2015) The proteasome inhibitor bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 74(7):1474\u20131478","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"9988_CR24","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nm1763","volume":"14","author":"K Neubert","year":"2008","unstructured":"Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K et al (2008) The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14(7):748\u2013755","journal-title":"Nat Med"},{"key":"9988_CR25","doi-asserted-by":"crossref","unstructured":"Scott K Hayden PJ Will A Wheatley K Coyne I (2016) Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev 4:CD010816","DOI":"10.1002\/14651858.CD010816.pub2"},{"key":"9988_CR26","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.3109\/10428194.2010.487959","volume":"51","author":"M Engelhardt","year":"2010","unstructured":"Engelhardt M, Kleber M, Udi J et al (2010) Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma 51:1424\u20131443","journal-title":"Leuk Lymphoma"},{"key":"9988_CR27","volume-title":"NCCN clinical practice guidelines in oncology multiple myeloma","author":"National comprehensive cancer network (NCCN)","year":"2011","unstructured":"National comprehensive cancer network (NCCN) (2011) NCCN clinical practice guidelines in oncology multiple myeloma. Fort Washington, PA (Ver. 1.2011)"},{"key":"9988_CR28","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","volume":"116","author":"S Bringhen","year":"2010","unstructured":"Bringhen S, Larocca A, Rossi D et al (2010) Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 116:4745\u20134753","journal-title":"Blood"},{"key":"9988_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/RHU.0000000000000210","volume":"21","author":"J Jakez-Ocampo","year":"2015","unstructured":"Jakez-Ocampo J, Atisha-Fregoso Y, Llorente L (2015) Refractory primary Sj\u00f6gren syndrome successfully treated with bortezomib. J Clin Rheumatol 21:31\u201332","journal-title":"J Clin Rheumatol"},{"issue":"8","key":"9988_CR30","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1001\/jamaneurol.2017.1336","volume":"74","author":"C Zhang","year":"2017","unstructured":"Zhang C, Tian DC, Yang CS, Han B, Wang J, Yang L et al (2017) Safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder. JAMA Neurol 74(8):1010\u20131026","journal-title":"JAMA Neurol"},{"issue":"11","key":"9988_CR31","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.4049\/jimmunol.1202317","volume":"189","author":"O Winter","year":"2012","unstructured":"Winter O, Dame C, Jundt F, Hiepe F (2012) Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy. J Immunol 189(11):5105\u20135111","journal-title":"J Immunol"},{"key":"9988_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.clineuro.2018.06.005","volume":"172","author":"C Schroeder","year":"2018","unstructured":"Schroeder C, Back C, Koc U, Strassburger-Krogias K, Reinacher-Schick A, Gold R et al (2018) Breakthrough treatment with bortezomib for a patient with anti-NMDAR encephalitis. Clin Neurol Neurosurg 172:24\u201326","journal-title":"Clin Neurol Neurosurg"},{"issue":"11","key":"9988_CR33","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1111\/ene.13759","volume":"25","author":"S Keddie","year":"2018","unstructured":"Keddie S, Crisp SJ, Blackaby J, Cox A, Coles A, Hart M et al (2018) Plasma cell depletion with bortezomib in the treatment of refractory N-methyl-d-aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment. Eur J Neurol 25(11):1384\u20131388","journal-title":"Eur J Neurol"},{"issue":"5","key":"9988_CR34","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/acn3.557","volume":"5","author":"YW Shin","year":"2018","unstructured":"Shin YW, Lee ST, Kim TJ, Jun JS, Chu K (2018) Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis. Ann Clin Transl Neurol 5(5):598\u2013605","journal-title":"Ann Clin Transl Neurol"},{"key":"9988_CR35","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487\u20132498","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1007\/s00415-020-10370-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000}}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-09988-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-020-09988-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-09988-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T23:26:07Z","timestamp":1623540367000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-020-09988-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,13]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["9988"],"URL":"https:\/\/doi.org\/10.1007\/s00415-020-09988-w","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00415-020-10370-z","asserted-by":"object"}]},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,13]]},"assertion":[{"value":"16 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00415-020-10370-z","URL":"https:\/\/doi.org\/10.1007\/s00415-020-10370-z","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No relevant competing interest was declared by the Authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Informed consent for publication was obtained verbally from the spouse for the usage of clinical data in anonymized fashion. The consent was audio-recorded in the presence of an independent witness.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The Ethics Committee of San Raffaele Scientific Institute waived the need for ethics approval for publication of case reports.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}